JP2020502218A - 骨形成不全症の処置における抗スクレロスチン抗体の使用 - Google Patents

骨形成不全症の処置における抗スクレロスチン抗体の使用 Download PDF

Info

Publication number
JP2020502218A
JP2020502218A JP2019533573A JP2019533573A JP2020502218A JP 2020502218 A JP2020502218 A JP 2020502218A JP 2019533573 A JP2019533573 A JP 2019533573A JP 2019533573 A JP2019533573 A JP 2019533573A JP 2020502218 A JP2020502218 A JP 2020502218A
Authority
JP
Japan
Prior art keywords
amino acid
patient
acid sequence
sclerostin antibody
sclerostin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019533573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502218A5 (OSRAM
Inventor
ユンカー，ウヴェ
クナイセル，ミカエラ
ケント ハル，アントニー
ケント ハル，アントニー
ジョイ ユディ，レナ
ジョイ ユディ，レナ
マニング リグス，マシュー
マニング リグス，マシュー
Original Assignee
メレオ バイオファーマ ３ リミテッド
メレオ バイオファーマ ３ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メレオ バイオファーマ ３ リミテッド, メレオ バイオファーマ ３ リミテッド filed Critical メレオ バイオファーマ ３ リミテッド
Publication of JP2020502218A publication Critical patent/JP2020502218A/ja
Publication of JP2020502218A5 publication Critical patent/JP2020502218A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2019533573A 2016-12-21 2017-12-21 骨形成不全症の処置における抗スクレロスチン抗体の使用 Pending JP2020502218A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437358P 2016-12-21 2016-12-21
US62/437,358 2016-12-21
PCT/GB2017/053849 WO2018115879A1 (en) 2016-12-21 2017-12-21 Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Publications (2)

Publication Number Publication Date
JP2020502218A true JP2020502218A (ja) 2020-01-23
JP2020502218A5 JP2020502218A5 (OSRAM) 2021-02-04

Family

ID=60888539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533573A Pending JP2020502218A (ja) 2016-12-21 2017-12-21 骨形成不全症の処置における抗スクレロスチン抗体の使用

Country Status (3)

Country Link
US (3) US10961305B2 (OSRAM)
JP (1) JP2020502218A (OSRAM)
WO (1) WO2018115879A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020502218A (ja) * 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
AU2017381433B2 (en) * 2016-12-21 2024-11-14 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
AU2022357544A1 (en) * 2021-09-30 2024-04-11 Mereo Biopharma 3 Limited Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta
WO2025036493A1 (en) * 2023-08-17 2025-02-20 Sinomab Bioscience Limited Antibodies targeting rankl and sclerostin and uses thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
SE8804164A0 (sv) 1988-11-17 1990-05-18 Per Prisell Farmaceutisk beredning
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5229495A (en) 1991-06-18 1993-07-20 Ludwig Institute For Cancer Research Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
ATE194658T1 (de) 1992-09-03 2000-07-15 Univ California Das dorsalgewebe beeinflussender faktor
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
JPH09512910A (ja) 1994-05-04 1997-12-22 マウント・サイナイ・ホスピタル・コーポレイション ＴＧＦ−βスーパーファミリーのサイトカインの変調因子およびそのアッセイ方法
US5616561A (en) 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
EP0975752A1 (en) 1997-04-29 2000-02-02 Regeneron Pharmaceuticals, Inc. Human cerberus protein
CA2292899A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
US5935852A (en) 1997-07-03 1999-08-10 Genetics Institute, Inc. DNA molecules encoding mammalian cerberus-like proteins
WO1999061044A1 (en) 1998-05-28 1999-12-02 The Board Of Trustees Of The University Of Arkansas Noggin and antagonists of bone morphogenetic proteins to suppress pathologic bone resorption
AU1071200A (en) 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
NZ512122A (en) 1998-11-27 2003-12-19 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
AU3511100A (en) 1999-03-12 2000-10-04 Regeneron Pharmaceuticals, Inc. Novel nucleic acids and polypeptides
US7358056B1 (en) 1999-08-30 2008-04-15 Signal Pharmaceuticals Methods for modulating signal transduction mediated by TGF-β and related proteins
WO2001047944A2 (en) 1999-12-28 2001-07-05 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
AU2001236519A1 (en) 2000-01-24 2001-07-31 Millennium Pharmaceuitcals, Inc. Identification, assessment, prevention, and therapy of prostate cancer
WO2001055388A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
US20040087016A1 (en) 2000-05-12 2004-05-06 University Of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
WO2001088103A2 (en) 2000-05-12 2001-11-22 University Of Utah Research Foundation Compositions and methods for tissue dedifferentiation and regeneration
EP1290169A2 (en) 2000-06-01 2003-03-12 Amgen, Inc. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
US20040132021A1 (en) 2000-06-19 2004-07-08 Wendy Balemans Osteolevin gene polymorphisms
AU2002236558A1 (en) 2000-12-01 2002-06-11 Regents Of The University Of California Method and composition for modulating bone growth
AU2002243495A1 (en) 2001-01-12 2002-07-24 University Of Medicine And Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
US20040235728A1 (en) 2001-11-08 2004-11-25 Stoch Selwyn Aubrey Compositions and methods for treating osteoporosis
CA2469941A1 (en) 2001-12-10 2003-07-03 Nuvelo, Inc. Novel nucleic acids and polypeptides
GB0130738D0 (en) 2001-12-21 2002-02-06 Serono Internat S A Protein
GB2385052A (en) 2002-02-05 2003-08-13 Leuven K U Res & Dev Treatment of spondyloarthropathies
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
JP2005253301A (ja) 2002-02-20 2005-09-22 Taisho Pharmaceut Co Ltd 骨形成蛋白結合領域を有する蛋白質及びそれをコードする遺伝子
US7332276B2 (en) 2002-03-01 2008-02-19 Celltech R&D, Inc. Methods to increase or decrease bone density
AU2003221841A1 (en) 2002-04-03 2003-10-27 Celltech R And D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
MXPA04011337A (es) 2002-05-17 2005-07-01 Wyeth Corp Portadores de acido hialuronico solidos y susceptibles de ser inyectados para la liberacion de proteinas osteogenicas.
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
WO2004041277A1 (en) 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
US20060276385A1 (en) 2003-01-13 2006-12-07 Hanjoong Jo Anti-inflammatory agents and methods of their use
WO2004082608A2 (en) 2003-03-14 2004-09-30 Celltech R & D, Inc. Ligands for tgf-beta binding proteins and uses thereof
CA2524409C (en) 2003-05-07 2011-12-20 Merck & Co., Inc. Androgen receptor modulators and methods of use thereof
AU2004262640B2 (en) 2003-06-16 2010-12-23 Ucb Manufacturing, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
AU2004269920A1 (en) 2003-09-11 2005-03-17 Association Francaise Retinitis Pigmentosa (Afrp) Novel targets for the treatment of retina diseases
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US20080249038A1 (en) 2003-10-07 2008-10-09 Quark Biotech, Inc. Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof
CN1976726A (zh) 2004-05-14 2007-06-06 贝勒医学院 用于调节骨量的组合物和方法
EP1751185A2 (en) 2004-05-27 2007-02-14 Acceleron Pharma Inc. Tgf derepressors and uses related thereto
US20110097330A1 (en) 2005-03-11 2011-04-28 Genentech, Inc. Novel Gene Disruptions, Compostitions and Methods Relating Thereto
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US20060293667A1 (en) 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
WO2006135734A2 (en) 2005-06-10 2006-12-21 The Regents Of The University Of California Compositions and methods for altering bone density and bone patterning
EP1981910B1 (en) 2006-01-13 2013-06-26 A Chan Holding B.V. Method for identifying inhibitor of the glypican-sclerostin interaction
EP2460828A3 (en) 2006-11-10 2012-08-08 UCB Pharma, S.A. Antibodies and diagnostics
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2144613B1 (en) 2006-12-29 2018-03-21 OstéoQC Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
EP2628486A3 (en) 2007-12-14 2013-10-30 Amgen, Inc. Method for treating bone fracture with anti-sclerostin antibodies
WO2010100200A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
WO2010115932A1 (en) * 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
US9617323B2 (en) 2010-06-07 2017-04-11 Joshua Rabbani Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
TWI636993B (zh) 2010-10-27 2018-10-01 安美基公司 Ｄｋｋ１抗體及使用方法
CN103649118A (zh) 2011-03-01 2014-03-19 安进公司 双特异性结合剂
SG10201701634PA (en) 2011-03-25 2017-04-27 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
EP2699261B1 (en) 2011-04-19 2018-07-11 Amgen Inc. Method for treating osteoporosis
AU2012290083B2 (en) 2011-08-04 2017-07-20 Amgen Inc. Method for treating bone gap defects
BR112014016108A2 (pt) 2011-12-28 2018-09-11 Amgen Inc método de tratamento de perda óssea alvelar
WO2014006100A1 (en) 2012-07-05 2014-01-09 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
LT3334747T (lt) 2015-08-13 2023-12-27 Amgen Inc. Įkrautas giluminis antigeną surišančio baltymo filtravimas
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
JP2019527710A (ja) 2016-08-08 2019-10-03 アムジエン・インコーポレーテツド 抗スクレロスチン抗体を用いた結合組織付着の改善方法
AU2017381433B2 (en) 2016-12-21 2024-11-14 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
US12503700B2 (en) 2017-03-14 2025-12-23 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
EP3659586B1 (en) 2017-07-27 2023-06-21 Jiangsu Hengrui Medicine Co., Ltd. Sost antibody pharmaceutical composition and uses thereof
SG11202009216YA (en) 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
CN112166120B (zh) 2018-03-30 2024-09-10 安姆根有限公司 C末端抗体变体
WO2020033788A1 (en) 2018-08-10 2020-02-13 Amgen Inc. Method of preparing an antibody pharmaceutical formulation

Also Published As

Publication number Publication date
US20210253687A1 (en) 2021-08-19
US20250122273A1 (en) 2025-04-17
WO2018115879A1 (en) 2018-06-28
US20190330322A1 (en) 2019-10-31
US10961305B2 (en) 2021-03-30
US12173058B2 (en) 2024-12-24

Similar Documents

Publication Publication Date Title
US20230365669A1 (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
JP6353500B2 (ja) Ｄｋｋ１抗体およびその使用方法
JP6845012B2 (ja) 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用
US20250122273A1 (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
KR101620771B1 (ko) Ｉｌ―17 길항제를 사용하는 건선의 치료 방법
KR20170045240A (ko) 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도
TW202323278A (zh) 使用抗硬骨抑素抗體治療成骨不全之方法
HK40058082A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
HK40007021B (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
HK40007021A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
TW202346345A (zh) 面肩胛肱肌失養症（ｆｓｈｄ）之新治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220510